Clinical proteomics in cancer: Where we are

Cancer Lett. 2016 Nov 28;382(2):231-239. doi: 10.1016/j.canlet.2016.08.014. Epub 2016 Aug 22.

Abstract

Proteomics has emerged as a promising field in the post-genomic era. Notwithstanding the great advances provided by gene expression analysis in cancer, the lack of a correlation between gene expression and protein levels has highlighted the need for a proteomic focus on cancer. Although the increasing knowledge regarding cancer biology, a reliable marker to improve diagnosis, prognosis and treatment for cancer patients is not a reality at present. In this review, we address the main considerations regarding proteomics-based studies and their clinical applications on cancer research, highlighting some considerations related to strengths and limitations of proteomics-based studies and its application to clinical practice.

Keywords: Cancer; Clinical proteomics; Mass spectrometry; Oncoproteomics; Proteomics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mass Spectrometry*
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Neoplasms / therapy
  • Predictive Value of Tests
  • Prognosis
  • Proteomics / methods*

Substances

  • Biomarkers, Tumor